If you are interested in learning more about emerging diagnostics, check out these sessions at the all-virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo.
Mass spectrometry of patient-derived specimens encompasses an expanding range of analytes and sample types. Mass spectrometric profiling and quantitation of endogenous metabolites, collectively termed "metabolomics," is routinely applied to research and pre-clinical specimens. Current and near-term applications of clinical metabolomics focus on high-resolution or tandem-quadrupole chromatography-mass spectrometry analysis of venipuncture and urinalysis specimens, with analytes ranging from small polar intermediates of glucose and energy metabolism to complex structural and signaling lipids. Learn more.
Identifying blood biomarkers for stroke is an active area of research. They can be used in diagnosis and differentiation of stroke in the acute setting, or to predict outcome and guide therapy. Although many biomarkers have been identified and tested in clinical studies, none are currently used for stroke management partly due to the very high specificity and sensitivity required. Nevertheless, some candidates have emerged for specific clinical indications and could be implemented in practice in the near future. Learn more.
This session is intended to provide a discussion about Traumatic Brain Injury (TBI). The session will be in 3 parts. Part I: Frank Peacock, MD, will describe the Emergency Department aspect of Traumatic Brain Injury (TBI). The presenting signs and symptoms for mild concussion will be discussed along with the current diagnostic tests that are conducted in the ED. The potential complementary role of blood biomarkers will be covered. Part II: Neil Datta, MD, will describe the neurological aspects of concussion and TBI including the condition, epidemiology, etiology, presentation, symptoms, evaluation through clinical exam and imaging, as well as the need for and potential outpatient role for biomarkers. Brief overview of management, and their connection to developing headaches and dementia will also be discussed. Part III: Alan Wu, PhD and Pradip Datta, PhD, will discuss the current clinical diagnostic markers including rule out and risk stratification. New potential biochemical markers for the disease, including markers of severity and prognosis, will also be discussed. Learn more.
This special session highlights one of AACC's new initiatives and strategic goals to enhance global healthcare through clinical diagnostics, with a special focus on clinical diagnostics in China. This session invites speakers from China to provide the current landscape of clinical practice and to showcase the new developments in molecular diagnostics. Learn more.
This session will provide an update on the rapidly evolving landscape of biomarkers and assays being developed for neurodegenerative proteinopathies including Alzheimer’s disease, frontotemporal degeneration, prion disease, and Parkinson’s disease. Learn more.
Join your community December 13-17 in Chicago for 5 days of scientific education, inspiration, and networking.